Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Newly discovered molecule effectively destroys senescent cells

Newly discovered molecule effectively destroys senescent cells

University Hospitals Birmingham partners with Qureight for lung disease research

University Hospitals Birmingham partners with Qureight for lung disease research

Researchers identify a major stem cell variant in lungs of patients with idiopathic pulmonary fibrosis

Researchers identify a major stem cell variant in lungs of patients with idiopathic pulmonary fibrosis

Protein inhibition could offer new strategies for treating severe asthma

Protein inhibition could offer new strategies for treating severe asthma

New type of nanoparticle can deliver messenger RNA encoding useful proteins to the lungs

New type of nanoparticle can deliver messenger RNA encoding useful proteins to the lungs

Study reveals synergistic impact of estrogen and intestinal dysbiosis on pulmonary fibrosis

Study reveals synergistic impact of estrogen and intestinal dysbiosis on pulmonary fibrosis

Chest CT reveals persistent lung abnormalities in patients two years post-COVID

Chest CT reveals persistent lung abnormalities in patients two years post-COVID

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

Scientists discover a protein in the lung that blocks SARS-CoV-2 infection

A review of innate immunity relevant to SARS-CoV-2 and COVID-19

A review of innate immunity relevant to SARS-CoV-2 and COVID-19

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Comprehensive lung cell atlas offers insights into an unexpected immune niche in the airways

Comprehensive lung cell atlas offers insights into an unexpected immune niche in the airways

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Collaborative work unravels hidden molecular secrets of age-related diseases

Collaborative work unravels hidden molecular secrets of age-related diseases

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

ASU scientists discover an unusual RNA biogenesis pathway

ASU scientists discover an unusual RNA biogenesis pathway

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

New white paper outlines the issues surrounding delays in diagnosing interstitial lung diseases

New white paper outlines the issues surrounding delays in diagnosing interstitial lung diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.